Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | 0.00% | 0.00% | 0.00% |
Mar. 05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
Feb. 27 | Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 3.29M 2.12M | Sales 2023 | 4.1M 2.64M | Capitalization | 25.69M 16.52M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.29M | Net income 2023 | -1M -643K | EV / Sales 2022 | 15 x |
Net cash position 2022 | 8.47M 5.45M | Net cash position 2023 | 4.08M 2.63M | EV / Sales 2023 | 5.26 x |
P/E ratio 2022 |
-22.6
x | P/E ratio 2023 |
-13.4
x | Employees | 4 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50.95% |
Current month | -16.67% |
Managers | Title | Age | Since |
---|---|---|---|
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 20-07-12 |
Brendon Lau
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 20-10-21 | |
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Alan Yamashita
BRD | Director/Board Member | 74 | 19-02-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 0.005 | 0.00% | 12,910 |
24-04-16 | 0.005 | 0.00% | 134,044 |
24-04-15 | 0.005 | -9.09% | 638,542 |
24-04-11 | 0.0055 | +10.00% | 265,678 |
Delayed Quote Australian S.E., April 16, 2024 at 08:04 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
0.00% | 20.62M | |
-1.07% | 41.36B | |
+45.26% | 41.3B | |
+3.20% | 39.61B | |
-15.14% | 25.62B | |
+4.15% | 24.09B | |
-23.70% | 18.38B | |
+24.82% | 11.85B | |
-2.33% | 11.82B | |
+8.80% | 11.07B |
- Stock Market
- Equities
- IVX Stock